This article was downloaded by: [Chulalongkorn University] On: 07 January 2015, At: 22:33 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

Synthesis and Anti-HIV Activity of Different Novel Nonclassical Nucleosides

Galal E. H. Elgemeie^a, Omar A. Mansour^b & Nadia H. Metwally^b ^a Chemistry Department, Faculty of Science, Helwan University, Helwan, Cairo, Egypt

^b Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt

Published online: 04 Oct 2006.

To cite this article: Galal E. H. Elgemeie , Omar A. Mansour & Nadia H. Metwally (1999) Synthesis and Anti-HIV Activity of Different Novel Nonclassical Nucleosides, Nucleosides and Nucleotides, 18:1, 113-123, DOI: <u>10.1080/07328319908045598</u>

To link to this article: http://dx.doi.org/10.1080/07328319908045598

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>

SYNTHESIS AND ANTI-HIV ACTIVITY OF DIFFERENT NOVEL NONCLASSICAL NUCLEOSIDES

Galal E. H. Elgemeie^{*}^a, Omar A. Mansour^b and Nadia H. Metwally^b a Chemistry Department, Faculty of Science, Helwan University, Helwan, Cairo, Egypt b Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt

ABSTRACT- A series of different novel nonclassical nucleosides have been synthesised and evaluated for their inhibitory activity against human immunodeficiency virus (HIV) replication in MT-4 cells.

Since the discovery of the human immunodeficiency virus (HIV) as the causative agent of the acquired immunodeficiency syndrome, there has been a high interest in compounds that can block the replication of retroviruses. Considering the importance of the virus-encoded reverse transcriptase in the replication of HIV, this enzyme is an attractive target for the design of new effective chemotherapeutic agents. Since the discovery of the utility of 3 '-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (DDI) as antiretroviral agents in spite of their toxic side effects, the synthesis of other drugs has been desirable. Recently, a new class of anti HIV-1 agents has been identified. These 1-(benzyloxymethy1)-5-ethyl-6-(phenylthio)uracil compounds like (EBPU) and 1-[(2hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT), show a high selectivity for the HIV-1 reverse transcriptase1. Other active related compounds related to HEPT and EBPU, like pyridinethione nucleosides were recently discovered in our laboratories, and all these compounds look promising as anti-HIV agents2-5 As an extension of our work on pyridinethione nucleosides, we report herein a novel synthesis of a new class of indano[1,2-b]pyridinethione nucleosides. The latter compounds will be considered as precursors of modified nucleosides. Also, we have tested these nucleosides against HIV.

Thus, it was found that cyanothioacetamide 1 reacted with the sodium salt of 2-(hydroxymethylene)-1-indanone 2 to give the indano[1,2-b]pyridine-2(1H)-thione 3. The structure of 3 was established on the basis of its elemental analysis and spectral data as well as its mass

spectrum which showed a molecular ion corresponding to $(M^+ 223)$. 1H-NMR spectroscopy also confirmed this structure for this product. Thus, 1H-NMR spectrum revealed a singlet at 7.77 ppm assigned for pyridine H-4 proton and a broad band at 13.80 ppm assigned to the N(1)proton, Compound 3 reacted with 2,3,4,6-tetra-O-acetyl-α-D-gluco- and -galacto-pyranosyl bromides in the presence of aqueous potassium hydroxide to give the correspounding Nglucoside 6a and N-galactoside 7a, respectively. Although the coupling of 3 with the glycosyl bromides could also give the corresponding thioglycosides, the formation of 6a and 7a was proved chemically. Reaction of 3 with hexamethyldisilazane (HMDS) in the presence of ammonium sulfate gave the corresponding 3-cyano-indano[1,2-b]-2-trimethylsilylthiopyridine 5, which was subsequently treated with peracetylated sugars in the presence of redistilled SnCl4 to afford the corresponding N-glycosyl compounds. All the previous literature reported that Lewis acid-induced coupling reactions of S-silvlated heterocyclic bases with peracetylated sugars gave the corresponding N- nucleosides as the sole heterocyclic product6,7. The structures of the reaction products 6a and 7a were established and confirmed by their elemental analyses and spectral data (MS, IR, UV, 1H-NMR, 13C-NMR). The analytical data for 6a revealed a molecular ion corresponding to $(M^+ 554)$. The 1H-NMR spectrum showed the anomeric proton as a doublet at 5.51-5.59 ppm with a spin-spin coupling constant of 8.30 Hz corresponding to a diaxial orientation of H-1' and H-2' protons and indicating the \beta-configuration, while the other six glucose protons resonated at 4.22-5.51 ppm. The ¹³C-NMR spectrum of **6a** contained a signal at 93.8 corresponding to the C-1' atom of the β -configuration. Four signals appearing at 67.5, 67.8, 70.1 and 71.1 ppm were assigned to C-6', C-4', C-2', C-3' and C-5', respectively. The UV spectrum of 6a proved that the reaction had led selectively to the formation of N-glycosyl derivatives and excluded substitution at the sulfur atom. Thus, whereas the S-methyl derivative of 3 showed two maxima at 275 (17.6) and 320 (7.8) nm, its N-glucosyl derivative exhibited three maxima at 268 (18.2), 322 (11.4) and 367 (22.3) nm. After deprotection of compounds 6a and 7a with a saturated solution of ammonia in methanol the free nucleosides 6b and 7b were obtained in almost quantitative yields, the structures of which were established on the basis of elemental analyses and spectral data. The analytical data for 7b reveal the molecular ion corresponding to $(M^+ 386)$. The 1H- NMR spectrum showed the anomeric proton as a doublet at 5.67 $(J_1'_2' =$ 9.70 Hz) ppm indicating the presence of only the β -D-configuration, while the signals of the four hydroxy groups of the glucose moiety are observed at 4.48-5.20 ppm (exchangable by D_2O). The 13C-NMR spectrum of 7b is characterized by a signal at 83.2 ppm corresponding to the C-1' atom of β -D- glucopyranose. Another five signals at 60.7, 69.7, 71.7, 78.8 and 81.6 ppm were assigned to C-6', C-4', C-2', C-3' and C-5', respectively. The 4-aryl-3-cyano-indano[1.2b]pyridine-2(1H)-thiones 10 were prepared bv the reaction of (arylmethylene)(cyano)thioacetamide 8 with 1-indanone 9 in boiling ethanol containing catalytic



amounts of piperidine. The structure of compounds 10 were established on the basis of their elemental analysis and spectral data (MS, IR, 1H-NMR). The mass spectrum of 10a was compatible with the molecular formula $C_{19}H_{10}CIN_2S$ (M⁺ 334) and The 1H-NMR spectrum had signals at 2.60 (s, CH₂), 7.21-8.02 (m, ArH) and 14.2 (br, NH) ppm. The formation of 10 from 8 and 9 proceeds most likely via addition of the active methylene group of 9 to the double bond of



13,14 Ar	R	
a, 4-ClC ₆ H ₄	Ac	
b, 4-CH ₃ C ₆ H ₄	Ac	
c, 4-CH ₃ OC ₆ H ₄	Ac	
d, 4-(CH ₃) ₂ NC ₆ H ₄	Âc	

Ar	<u></u> R
e, 4-CIC ₆ H ₄	Н
f, 4-CH ₃ C ₆ H ₄	H
g. 4-CH ₃ OC ₆ H ₄	Н
h, 4-(CH ₃) ₂ NC ₆ H ₄	Н

Table 1: Comparative potency and selectivity of 3-cyano-1-(2,3,4,6-tetra-O-acetyl- β -D-glucoand-galactopyranosyl)-indano[1,2-b]pyridine-2(1H)-thiones 13c, 13e and 14a as inhibitors of HIV replication in MT-4 cells.

Compd	EC ₅₀ a	IC ₅₀ b	TIC	
	μΜ	μΜ	(ratio IC ₅₀ / EC ₅₀)	
13c	1.79	8.91	4.98	
13e	0.166	3.01	18.1	
14a	5.56	8.76	1.57	

a. Approximate values for 50% effective concentration of MT-4 cells against the cytopathic effect of HIV (EC₅₀).

b. Inhibitory concentration for 50% (IC₅₀).

c. Therapeutic index TI (IC₅₀/EC₅₀).

8 to give intermediate Michael adducts, which then cyclize via water elimination and oxidation under the reaction conditions to yield **10**. Compounds **10** reacted with 2,3,4,6-tetra-O-acetyl- α -Dgluco- and -galacto-pyranosyl bromides in the presence of aqueous potassium hydroxide via an intermediary acyl oxonium ion to afford the corresponding N-glucosides **13a-d** and Ngalactosides **14a-d**. The structures of the reaction products **13a-d** and **14a-d** were established and confirmed on the basis of their elemental analyses and spectral data (MS, IR, UV, 1H-NMR, 13C-NMR). When compounds **13a-d** and **14a-d** were treated with methanolic ammonia at 0° C, the free glycoside derivatives **13e-h** and **14e-h** were obtained, the structures of which were established on the basis of elemental analysis and spectral data. The IR spectrum of **13e** showed a band at 3600-3200 cm⁻¹ due to the hydroxy groups of the glucose moiety. The 1H-NMR spectrum showed the anomeric proton as a doublet at 5.42 (J_{1',2'} = 9.55 Hz) ppm indicating the presence of only the β -configuration. The other six glucose protons appeared as a multiplet at 3.18-3.70 ppm, while the four hydroxy groups of the glucose moiety resonated at 4.40-5.18 ppm (exchangeable by D₂O).

Antiviral Activity

The anti-HIV activity and cytotoxicity of the indano[1,2-b]pyridine-2(1H)-thione nucleoside derivatives are shown inTable 1. Among the acetylated derivatives, compound 13c turned out to be the most selective anti-HIV agent, followed by 14a. The other compounds were virtually devoid of any anti-HIV activity. Among the free glycoside derivatives, the free nucleoside 13e proved clearly more active and selective than the corresponding protected derivative. None of the other rest of free sugars showed any selectivity and/or antiviral activity. Since compounds 6, 7, 13 and 14 belong to a new class of active nucleosides and also were active against HIV, further investigations are needed in order to determine the mechanism of their action against HIV.

Experimental

All evaporations were carried out under reduced pressure at 40° C. Melting points were uncorrected. Aluminium sheets [silica gel 60 F₂₅₄ (Merck)] were used for TLC; spots were detected by viewing under a short-wavelength UV lamp. IR spectra were obtained (KBr disc) on a Pye Unicam Spectra-1000 spectrophotometer. 1H-NMR and 13C-NMR spectra were measured on Wilmad 270 MHz or Varian 400 MHz spectrometers for solution in (DMSO-d₆ or CDCl₃) using SiMe4 as internal standard. Mass spectra were recorded on a Varian MAT 112 spectrometer. Analytical data were obtained from the Microanalytical Data Center at Cairo University.

3-Cyano-indano[1,2-b]pyridine-2(1H)-thione 3.

A solution of 2-(hydroxymethylene)-1-indanone 2 (0.01mol), cyanothioacetamide 1 (0.01mol) and piperidine acetate (0.95 ml) [prepared from glacial acetic acid (0.42 ml), water (1ml) and piperidine (0.72 ml)] in water (5 ml) was refluxed for 10 minutes. Acetic acid (1.5 ml) was added to the hot solution. The precipitated solid was collected by filtration and recrystallized from the appropriate solvent.

3: mp 250 °C, yield 90%. IR (KBr) υ 2220 (CN), 3450-3400 (NH); 1H-NMR (DMSO-d₆) δ 2.32 (s, 2H, CH₂), 7.77 (s, 1H, pyridine H-4), 7.60-8.02 (m, 4H, Ar-H), 13.80 (s, br, 1H, NH); m/z 223 (Found: C, 69.8; H, 3.0; N, 12.3; S, 14.1. C₁₃H₇N₂S calculated C, 70.0; H, 3.1; N, 12.5; S, 14.3%).

4-Aryl-3-cyano-indano[1,2-b]pyridine-2(1H)-thiones 10a-d.

To a mixture of (arylmethylene)(cyano)thioacetamides (0.01 mol) **8a-d** and 1-indanone **9** (0.01 mol) in ethanol (50 ml) was added, piperidine (0.3 ml). The reaction mixture was heated under reflux for 3 hr, and then set aside overnight. The resultant precipitate was filtered off and recrystallized from EtOH/dioxane to yield coloured crystals.

10a: mp 295 °C, yield 93%. IR (KBr) υ 2221 (CN), 3450-3400 (NH); 1H-NMR (DMSO-d₆) δ 2.60 (s, 2H, CH₂), 7.21-8.02 (m, 8H, Ar-H), 14.20 (s, br, 1H, NH); m/z 334 (Found: C, 68.0; H, 2.7; N, 8.6; S, 9.7. C₁₉H₁₀ClN₂S calculated C, 68.2; H, 3.0; N, 8.5; S, 9.5%).

10b: mp 240 °C, yield 85%. IR (KBr) υ 2220 (CN), 3450-3400 (NH); 1H-NMR (DMSO-d₆) δ 2.35 (s, 3H, CH₃), 2.60 (s, 2H, CH₂), 7.40-8.10 (m, 8H, Ar-H), 13.95 (s, br, 1H, NH); m/z 313 (Found: C, 76.8; H, 3.9; N, 9.1; S, 10.0. C₂₀H₁₃N₂S calculated C, 76.6; H, 4.1; N, 8.9; S, 10.2%).

10c: mp 288 °C, yield 85%. IR (KBr) υ 2219 (CN), 3450-3400 (NH); 1H-NMR (DMSO-d₆) δ 2.67 (s, 2H, CH₂), 3.75 (s, 3H, OCH₃), 7.40-8.20 (m, 8H, Ar-H), 14.10 (s, br, 1H, NH); m/z 329 (Found: C, 73.1; H, 3.8; N, 8.7; S, 9.5. C₂₀H₁₃N₂OS calculated C, 72.9; H, 4.0; N, 8.5; S, 9.7%).

10d: mp 310 °C, yield 87%. IR (KBr) \cup 2221(CN), 3450-3400 (NH); 1H-NMR (DMSO-d₆) δ 2.60 (s, 2H, CH₂), 2.68 (s, 6H, 2CH₃), 7.45-8.15(m, 8H, Ar-H), 14.21(s, br, 1H, NH); m/z 342 (Found: C, 73.4; H, 4.4; N, 12.0; S, 9.5. C₂₁H₁₆N₃S calculated C, 73.6; H, 4.6; N, 12.2; S, 9.3%).

3-Cyano-1-(2,3,4,6-tetra-O-acetyl-β-D-gluco- and -galactopyranosyl)-indano[1,2-b]pyridine-2(1H)-thiones 6a, 7a , 13a-d and 14a-d.

General procedure:

Method A. To a solution of the 3-cyano-indano[1,2-b]pyridine-2(1H)-thione 3 and/or 3-cyano-4arylindano[1,2-b]pyridine-2(1H)-thiones 10a-d (0.01 mol) in aqueous potassium hydroxide [0.56 g (0.01 mol) in 6 ml of distilled water], a solution of 2,3,4,6-tetra-O-acetyl- α -D-gluco- or -galacto-pyranosyl bromide (4.52 g, 0.01 mol) in acetone (30 ml) was added. The reaction mixture was stirred at room temperature for 60 min, then evaporated under reduced pressure at 40 °C, and the residue washed with distilled water to remove the formed potassium bromide. The product was dried and recrystallized from ethanol to afford pale yellow crystals.

Method B. The 3-cyano-indano[1,2-b]pyridine-2(1H)-thione 3 and /or 3-cyano-4-aryl-indano-[1,2-b]pyridine-2(1H)-thiones 10a-d (0.01 mol) were boiled under reflux and anhydrous conditions for 48 hours with hexamethyldisilazane (25 ml) and $(NH_4)_2SO_4$ (0.02 g). The excess hexamethyldisilazane was removed under diminished pressure to provide the silylated bases 5 and 12 as a colourless oils. To a solution of the silylated base in dry MeCN (30 ml), a solution of α -D-glucose- or α -D-galactose pentaacetate (0.01 mol) in dry MeCN (20 ml) was added followed by the addition of SnCl₄ (1.6 ml). The reaction mixture was stirred at room temperature until the reaction was completed as indicated by TLC (3 to 6 h). The solution was poured into a saturated NaHCO₃ solution and extracted with CHCl₃. The organic layers were dried over MgSO₄, filtered and concentrated to give the crude nucleosides which were purified by recrystallization from EtOH to afford pale yellow crystals.

6a: mp 220 °C, yield 70%. UV (EtOH), λmax 268 (18.2), 322 (11.4), 367 (22.3) nm; IR (KBr) 2218 (CN), 1745(CO); 1H-NMR (DMSO-d₆) δ 1.99-2.05 (4s, 12H, 4CH₃CO), 2.32 (s, 2H, CH₂), 3.84 (m, 1H, H-5'), 4.22 (d, 2H, 2H-6'), 5.10-5.51 (m, 3H, H-4', H-3', H-2'), 5.95 (d, 1H, H-1'), 7.30-8.0 (m, 4H, Ar-H), 8.40 (s, 1H, pyridine H-4); m/z 554 (Found: C, 58.6; H, 4.8; N, 5.2; S, 5.8. C₂₇H₂₆N₂O₉S calculated C, 58.4; H, 4.7; N, 5.0; S, 5.7%).

7a: mp 220 °C, yield 70%. IR (KBr) 2219 (CN), 1746(CO); 1H-NMR (DMSO-d₆) δ 1.98-2.05 (4s, 12H, 4CH₃CO), 2.34 (s, 2H, CH₂), 3.84 (m, 1H, H-5'), 4.22 (d, 2H, 2H-6'), 5.10-5.40 (m,

3H, H-4', H-3', H-2'), 5.95 (d, 1H, H-1'), 7.30-8.0 (m, 4H, C₆H₄), 8.40 (s, 1H, pyridine H-4); m/z 554 (Found: C, 58.3; H, 4.6; N, 5.2; S, 5.5. $C_{27}H_{26}N_2O_9S$ calculated C, 58.4; H, 4.7; N, 5.0; S, 5.7%).

13a: mp 196 °C, yield 85%. IR (KBr) 2222 (CN), 1744(CO); 1H-NMR (DMSO-d₆) δ 1.98-2.05 (4s, 12H, 4CH₃CO), 2.60 (s, 2H, CH₂), 3.90 (m, 1H, H-5'), 4.10 (d, 2H, 2H-6'), 5.11-5.37 (m, 3H, H-4', H-3', H-2'), 5.93 (d, 1H, H-1'), 7.35-8.02 (m, 8H, 2C₆H₄); m/z 664 (Found: C, 59.4; H, 4.5; N, 4.1; S, 4.6. C₃₃H₂₉ClN₂O₉S calculated C, 59.5; H, 4.3; N, 4.2; S, 4.8%).

13b: mp 180 °C, yield 75%. IR (KBr) 2222 (CN), 1745(CO); 1H-NMR (DMSO-d₆) δ 1.99-2.04 (4s, 12H, 4CH₃CO), 2.05 (s, 3H, CH₃), 2.65 (s, 2H, CH₂) 3.90 (m, 1H, H-5'), 4.40 (d, 2H, 2H-

6'), 5.61-6.0 (m, 3H, H-4', H-3', H-2'), 6.25 (d, $J_{1,2}$ 10.32 Hz, 1H, H-1''), 7.35-8.02 (m, 8H, 2C₆H₄); m/z 644 (Found: C, 63.0; H, 5.1; N, 4.5; S, 4.7. C₃₄H₃₂N₂O₉S calculated C, 63.2; H, 4.9; N, 4.3; S, 4.9%).

13c: mp 205 °C, yield 86%. IR (KBr) 2210 (CN), 1746(CO); 1H-NMR (DMSO-d₆) δ 1.98-2.02 (4s, 12H, 4CH₃CO), 2.35 (s, 2H, CH₂), 2.75 (s, 3H, OCH₃) 3.95 (m, 1H, H-5'), 4.08-4.16 (d, 2H, 2H-6'), 5.50 (m, 3H, H-4', H-3', H-2'), 6.30 (d, J_{1,2} 10.22 Hz, 1H, H-1''), 7.20-8.0 (m, 8H, 2C₆H₄); m/z 660 (Found: C, 61.6; H, 4.6; N, 4.0; S, 4.6. C₃₄H₃₂N₂O₁₀S calculated C, 61.6; H, 4.7; N, 4.2; S, 4.8%).

13d: mp 215 °C, yield 78%. IR (KBr) 2222 (CN), 1744(CO); 1H-NMR (DMSO-d₆) δ 1.99-2.04 (4s, 12H, 4CH₃CO), 2.63 (s, 2H, CH₂), 2.70 (s, 6H, 2CH₃), 3.90 (m, 1H, H-5'), 4.40 (d, 2H, 2H-6'), 5.61-6.0 (m, 3H, H-4' H-3', H-2'), 6.25 (d, J_{1,2} 10.32 Hz, 1H, H-1'), 7.35-8.02 (m, 8H, 2C₆H₄); m/z 673 (Found: C, 62.1; H, 4.9; N, 6.0; S, 4.5. C₃₅H₃₅N₃O₉S calculated C, 62.4; H, 5.2; N, 6.2; S, 4.7%).

14a: mp 185 °C, yield 75%. IR (KBr) 2210 (CN), 1750(CO); 1H-NMR (DMSO-d₆) δ 1.78-2.02 (4s, 12H, 4CH₃CO), 2.60 (s, 2H, CH₂), 3.85 (m, 1H, H-5'), 4.60 (d, 2H, 2H-6'), 5.20-5.62 (m, 3H, H-4', H-3', H-2'), 6.31 (d, 1H, H-1'), 7.40-8.02 (m, 8H, 2C₆H₄); m/z 664 (Found: C, 59.4; H, 4.4; N, 4.0; S, 4.9. C₃₃H₂₉ClN₂O₉S calculated C, 59.6; H, 4.3; N, 4.2; S, 4.8%).

14b: mp 173 °C, yield 80%. IR (KBr) 2215 (CN), 1755(CO); 1H-NMR (DMSO-d₆) δ 1.99-2.04 (4s, 12H, 4CH₃CO), 2.05 (s, 3H, CH₃), 2.60 (s, 2H, CH₂) 3.80 (m, 1H, H-5'), 4.42 (d, 2H, 2H-

6'), 5.55-6.10 (m, 3H, H-4', H-3', H-2'), 6.20 (d, $J_{1,2}$ 10.32 Hz, 1H, H-1'), 7.20-8.10 (m, 8H, $2C_{6}H_{4}$); m/z 644 (Found: C, 63.1; H, 5.1; N, 4.5; S, 4.7. $C_{34}H_{32}N_{2}O_{9}S$ calculated C, 63.3; H, 4.9; N, 4.3; S, 4.9%).

14c: mp 175 °C, yield 84%. IR (KBr) 2210 (CN), 1752(CO); 1H-NMR (DMSO-d₆) δ 1.99-2.10 (4s, 12H, 4CH₃CO), 2.30 (s, 2H, CH₂), 3.85(s, 3H, OCH₃), 3.85 (m, 1H, H-5'), 4.60-4.80 (d, 2H, 2H-6'), 5.21-5.80 (m, 3H, H-4', H-3', H-2'), 6.35 (d, J_{1,2} 10.12 Hz, 1H, H-1''), 7.10-8.40 (m, 8H, 2C₆H₄); m/z 660 (Found: C, 61.6; H, 4.6; N, 4.0; S, 4.7. C₃₄H₃₂N₂O₁₀S calculated C, 61.8; H, 4.8; N, 4.2; S, 4.8%).

14d: mp 160 °C, yield 80%. IR (KBr) 2210 (CN), 1751(CO); 1H-NMR (DMSO-d₆) δ 1.82-2.20 (4s,12H, 4CH₃CO), 2.65 (s, 2H, CH₂), 3.00 (s, 6H, 2CH₃), 3.85 (m, 1H, H-5'), 4.60 (d, 2H, 2H-6') 5.22-5.85 (m, 3H, H-4', H-3'H-2'), 6.35 (d, J_{1,2} 10.20 Hz, 1H, H-1'), 7.35-8.20 (m, 8H, 2C₆H₄); m/z 673 (Found: C, 62.6; H, 5.3; N, 6.0; S, 4.5. C₃₅H₃₅N₃O₉S calculated C, 62.4; H, 5.2; N, 6.2; S, 4.7%).

3-Cyano-1-(β -D-gluco- and -galactopyranosyl)-indano- pyridine-2(1H)-thiones 6b, 7b , 13e-h and 14e-h.

General procedure:

Dry gaseous NH_3 was passed through a solution of protected nucleosides **6a**, **7a**, **13a-d** and **14a-d** (0.5 g) in dry MeOH (25 ml) at 0 °C for about 0.5 h, then the reaction mixture was stirred until judged complete by TLC (4 to 18 h). The resulting reaction mixture was evaporated under reduced pressure at 40 °C giving a solid residue which was crystallized from EtOH to afford pale yellow crystals.

6b: mp 200 °C, yield 70%. IR (KBr) 2218 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.65 (s, 2H, CH₂), 3 .15-3.80 (m, 6H, 2H-6', H-5',H-4', H-3' and H-2'), 4.55 (m, 2H,OH-1' and OH-3'), 5.02 (d, J 9.8 Hz, 1H, OH-4'), 5.35 (d, J 10.5 Hz, 1H, OH-6'), 5.65 (d, J_{1,2} 10.55 Hz, 1H, H-1'), 7.27-7.99 (m, 4H, C₆H₄), 8.32 (s, 1H, pyridine H-4); m/z 386 (Found: C, 59.2; H, 4.4; N, 7.0; S, 8.0. C₁9H₁₈N₂O₅S calculated C, 59.0; H, 4.6; N, 7.2; S, 8.3%).

7b: mp 200°C, yield 70%. IR (KBr) 2218 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.74 (s, 2H, CH₂), 3 .23-3.71 (m, 6H, 2H-6', H-5', H-4', H-3'and H-2'), 4.48 (t, 1H, 3'-OH), 5.00 (d, 1H,2'-OH), 5.02 (d, J 10 Hz, 1H, 4'-OH), 5.67 (d, J_{1',2}' = 9.70 Hz, 1H, 1'-OH and 1H, 6'-OH'), 6.92-7.82 (m, 4H, C₆H₄), 8.09 (s, 1H, pyridine H-4); 13C-NMR (DMSO) δ 26.4 (CH₂), 60.7 (C-6'), 69.7 (C-4'), 71.7 (C-2'), 78.8 (C-3'), 81.6 (C-5'), 83.2 (C-1'), 107.0 (C-4), 115 (CN), 122.2-138.2 (aromatic-C), 153.8 (C-5), 157.3 (C-6), 158.4 (C-3) and 163.1 (C=S); m/z 386 (Found: C, 59.3; H, 4.4; N, 7.4; S, 8.1. C₁₉H₁₈N₂O₅S calculated C, 59.0; H, 4.6; N, 7.2; S, 8.3%).

13e: mp 250 °C, yield 70%. IR (KBr) 2219 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.75 (m, 4H, 2CH₂), 3 .18-3.70 (m, 6H, 2H-6', H-5'H-4', H-3'and H-2'), 4.40 (t, 1H, H-4', H-3',

H-2'), 5.02 (d, 1H, 2'-OH), 5.18 (d, J 9.8 Hz, 1H, 4'-OH), 5.42 (d, $J_{1',2'} = 9.55$ Hz, 1H, H-1'and 1H, 6'-OH), 7.02-8.00 (m, 8H, 2C₆H₄); 13C-NMR (DMSO) δ 28.6 (CH₂), 60.2 (C-6'), 66.6 (C-4'), 71.9 (C-2'), 79.5 (C-3'), 82.3 (C-5'), 85.2 (C-1'), 105.2 (C-3), 116.2 (CN), 127.2-162.3 (Ar-C), 150.2 (C-5), 152.9 (C-6), 156.2 (C-4) and 162.2 (C=S); m/z 497 (Found: C, 60.1; H, 4.0; N, 5.3; S, 6.2. C₂₅H₂₁ClN₂O₅S calculated C, 60.3; H, 4.2; N, 5.6; S, 6.4%).

13f: mp 250 °C, yield 70%. IR (KBr) 2219 (CN), 3600-3200 (OH); m/z 476 (Found: C, 65.3; H, 4.8; N, 5.1; S, 6.5. C₂₆H₂₄N₂O₅S calculated C, 65.5; H, 5.0; N, 5.8; S, 6.7%).

13g: mp 250 °C, yield 70%. IR (KBr) 2219 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.62 (m, 4H, 2CH₂), 3.22-3.80 (m, 6H, 2H-6', H-5',H-4', H-3'and H-2'), 3.92 (s, 3H, OCH₃), 4.58 (m, 2H, 2'-OH and 3'-OH), 4.92 (t, 1H, 4'-OH), 5.36 (t, 1H, 6'-OH), 5.62 (d, $J_{1',2'} = 9.72$ Hz, 1H, H-1'), 6.92-8.05 (m, 8H, 2C₆H₄); m/z 492 (Found: C, 63.2; H, 4.6; N, 5.5; S, 6.5. C₂₆H₂₄N₂O₆S calculated C, 63.4; H, 4.8; N, 5.7; S, 6.3%).

13h: mp 250 °C, yield 70%. IR (KBr) 2219 (CN), 3600-3200 (OH); m/z 505 (Found: C, 63.9; H, 5.1; N, 8.1; S, 6.1. C₂₇H₂₇N₃O₅S calculated C, 64.1; H, 5.3; N, 8.3; S, 6.3%).

14e: mp 250 °C, yield 70%. IR (KBr) 2220(CN), 3600-3200 (OH); m/z 497 (Found: C, 60.5; H, 4.4; N, 5.3; S, 6.2. C₂₅H₂₁ClN₂O₅S calculated C, 60.3; H, 4.2; N, 5.6; S, 6.4%).

14f: mp 250 °C, yield 75%. IR (KBr) 2216 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.35 (s, 3H, CH₃), 2.65 (s, 2H, CH₂), 3.25-3.82 (m, 6H, 2H-6', H-5', H-4', H-3'and H-2'), 4.22 (t, 2H, 2'-OH and 3'-OH) 4.69 (d,1H,4'-OH), 5.42 (d, 1H, 6'-OH), 5.67 (d, 1H, d, J_{1',2'} =10.30 Hz, H-1'), 7.02-8.09 (m, 8H, 2C₆H₄); m/z 476 (Found: C, 65.7; H, 4.8; N, 5.10; S, 6.5. C₂₆H₂₄N₂O₅S calculated C, 65.5; H, 5.0; N, 5.8; S, 6.7%).

14g: mp 250 °C, yield 78%. IR (KBr) 2219 (CN), 3600-3200 (OH); m/z 492 (Found: C, 63.6; H, 4.6; N, 5.5; S, 6.5. C₁₉H₁₈N₂O₅S calculated C, 63.4; H, 4.8; N, 5.7; S, 6.6%).

14h: mp 250 °C, yield 70%. IR (KBr) 2219 (CN), 3600-3200 (OH); 1H-NMR (DMSO-d₆) δ 2.51 (s, 2H, CH₂), 2.68 (s, 6H, 2CH₃), 3.32-3.73 (m, 6H, 2H-6', H-5', H-4', H-3'and H-2'), 4.50 (s, 2H, 2'-OH and 3'-OH) 4.88 (s,1H, 4'-OH), 5.28 (s, 1H, 6'-OH), 5.55 (d, 1H, d, $J_{1',2'}$ =10.09 Hz, H-1'), 7.11-8.10 (m, 8H, 2C₆H₄); m/z 505 (Found: C, 63.9; H, 5.1; N,8.1; S,6.1. C₂₇H₂₇N₃O₅S calculated C, 64.1; H, 5.3; N, 8.3; S, 6.3%).

Biological Procedure

The compounds **6a-b**, **7a-b**, **13a-h** and **14a-h**, were dissolved in dimethyl sulfoxide then diluted 1:100 in cell culture medium before preparing serial half-log₁₀ dilutions. T₄ lymphocytes were added and after a brief interval HIV-1 was added, resulting in 1:20 final dilution of the compound. Uninfected cells with the compound served as a toxicity control, and infected and uninfected cells without the compound served as basic controls. Cultures were incubated at 37°C in a 5% carbon dioxide atmosphere for 6 days. The tetrazolium salt, XTT, was added to all wells, and cultures were incubated to allow formazan color development by viable cells. Individual wells were analyzed spectrophotometrically to quantitate formazan production, and in addition were viewed microscopically for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells were compared with drug-treated noninfected cells and with other appropriate controls on the same plate. Data were reviewed in comparison with other tests done at the same time and a determination about activity was made.

References

- Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balzarini, J. and De Clereq, E. A., J. Med. Chem., 1989 32, 2507.
- 2) Elgemeie G. E. H.; Attia, A. M.; Farag D. S. and Sherif, S. M. J. Chem. Soc. Perkin Trans., 1 1994, 1285.
- 3) Elgemeie, G. E. H.; Attia A. M. and Fathy, N. M. Liebigs Ann. Chem., 1994, 955.
- 4) Elgemeie, G. E. H.; Attia, A. M.; Elzanate A. M. and Mansour, A. K., Bull. Chem. Soc. Jpn., 1994 67, 1627.
- 5) Elgemeie, G. H. and Bates, S. E., Developmental Therapeutics Program, NSC 667739, 676597, 676599, 676600, 676605, NCI, Maryland, U. S. A., **1997**.
- 6) Niedballa, U. and Vorbruggen, H. J. Org. Chem., 1974 39, 3654, 3668.
- 7) Lichtenthaler, F. W.; Voss, P. and Heerd, A. Tetrahedron Lett., 1974, 214.

Received 11/4/97 Accepted 9/2/98